Trial results

Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

NCT07754045 on ClinicalTrials.gov · last registry update 2026-08-10

Registered but not yet open, with 202 participants planned. Due to report 15 February 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Lumos Pharma

Sponsor type

Industry

Enrollment

202

Started

2027-02-15

Primary completion

2028-02-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26.

Conditions studied

Obesity & Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.